Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS) are likely to receive programmed cell death 1 (PD-1) inhibitors, despite limited evidence. The aim of the present study was to report the clinical outcomes and potential prognostic biomarkers in advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shixue, Li, Ruixin, Zhang, Zhibo, Huang, Ziwei, Cui, Pengfei, Jia, Wangping, Zhang, Sujie, Tao, Haitao, Wang, Lijie, Li, Xiaoyan, Wang, Jinliang, Ma, Junxun, Liu, Zhefeng, Huang, Di, Zheng, Xuan, Saito, Yuichi, Ichiki, Yoshinobu, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044483/
https://www.ncbi.nlm.nih.gov/pubmed/33889518
http://dx.doi.org/10.21037/tlcr-21-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044483/
https://www.ncbi.nlm.nih.gov/pubmed/33889518
http://dx.doi.org/10.21037/tlcr-21-43

Ejemplares similares